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Available online xxxxObjective: The aim of this study was to examine DNA ligase activity and expression of DNA damage response
pathway (DDR) genes in patients with stable angina (SA) and non-ST elevation myocardial infarction (NSTEMI)
and determine whether they correlate with plaque morphology.
Background: Patients with coronary artery disease (CAD) have evidence of deoxyribonucleic acid (DNA) damage
in peripheral bloodmononuclear cells (PBMCs). It is unclear whether this represents excess damage or defective
DNA repair activity.
Methods: DNA ligase activity and the expression of 22 DDR genes were measured in PBMCs of patients (both SA
(n = 47) and NSTEMI (n = 42)) and in age and gender-matched controls (n = 35). Target lesion anatomical
assessment was undertaken with frequency domain optical coherent tomography.
Results: DNA ligase activity was different across the three groups of patients (control = 119 ± 53, NSTEMI =
115.6± 85.1, SA=81±55.7 units/g of nuclear protein; ANOVA p=0.023). Pairwise comparison demonstrated
that this significance is due to differences between the control and SA patients (p= 0.046). Genes involved in
double strand break repair and nucleotide excision repair pathways were differentially expressed in patients
with SA and NSTEMI. In SA patients, fibrocalcific plaques were strongly associated with GTSE1, DDB1, MLH3
and ERCC1 expression. By contrast, in NSTEMI patients the strongest association was observed between fibrous
plaques and ATM and XPA expression.
Conclusion: PBMCs from patients with CAD exhibit differences in DNA ligase activity and expression of DDR
genes. Expression levels of certain DDR genes are strongly associated with plaque morphology and may play a
role in plaque development and progression.
Trial Registration Number
URL: www.Clinicaltrials.gov; NCT02335086
© 2019 Elsevier Inc. All rights reserved.Keywords:
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FD-OCT1. Introduction
Atherosclerotic coronary artery disease (CAD) and its complications
remain themost common cause ofmorbidity andmortality in theWest-
ern World [1]. Both atherosclerotic plaques and circulating leukocytes
in patients with CAD show markers of deoxyribonucleic acid (DNA)Sciences, Southampton General
oudi).
R.M. Elliott, et al., DNA damag
scularization Medicine, https:damage and activation of the DNA damage response pathway (DDR)
suggesting that DNA damage may contribute to atherogenesis [2–4].
DNAdamage is seen in early atherosclerotic lesions and becomes almost
universal in advanced plaques [5]. However, it is unclear whether ele-
vated DNA damage reflects increased exposure to damage-causing
agents, defective DNA repair, or both. Furthermore, DNA repair activity
and how it correlates with plaque morphology has not been studied in
CAD patients.
A major cause of DNA damage in atherosclerosis is oxidative stress
[6]. The DNA repair pathways most pertinent to oxidative stress aree and repair in patients with coronary artery disease: Correlationwith
//doi.org/10.1016/j.carrev.2019.04.028
2 N. Shah et al. / Cardiovascular Revascularization Medicine xxx (xxxx) xxxthe double strand break repair (DSBR) and base excision repair (BER)
pathways. The importance of DNA repair activity, which may be mea-
sured in vitro using DNA ligase assays, in atherosclerosis is illustrated
by premature aging disorders such asWerner syndromewhereby a de-
ficiency in theWRN protein required for DSBR and BER leads to acceler-
ated aging and atherosclerosis [7]. In addition, cultured plaque vascular
smooth muscle cells (VSMCs) exhibit differential activation of 22 genes
frommultiple DNAdamage and repair pathways, butmost notably from
those involved in BER and DSBR [8].
The aims of this study were to: (a) measure DNA repair using DNA
ligase activity as well as the expression of a set of 22 DDR gens in
PBMCs from patients with stable and unstable CAD, and (b) determine
whether differences in DNA repair and/or gene expression correlate
with plaque morphology as assessed by frequency domain optical co-
herence tomography (FD-OCT).
2. Methods
The DNA Damage and Repair in Patients with Coronary Artery
Disease (DECODE) study was a prospective study approved by the
Research Ethics Service Committee South East Coast-Surrey, UK (REC
Reference: 13/LO/0238, IRAS Project ID: 120221) and is registered at
ClinicalTrials.gov (NCT02335086). All participants gave written in-
formed consent before enrolment. Consecutive patients undergoing
percutaneous coronary intervention (PCI) for symptomatic stable an-
gina (SA) despite optimal medical therapy or non-ST elevationmyocar-
dial infarction (NSTEMI) were prospectively enrolled. Age and gender-
matched patients being investigated for chest pain and who were
found to have normal coronary arteries upon coronary angiography
were also recruited and served as the control armof the study. Exclusion
criteria were age ≥ 80 years, inability to provide informed consent, pre-
sentation with ST-elevation myocardial infarction, decompensated
heart failure, left ventricular ejection fraction ≤ 35%, prior coronary re-
vascularization (surgical or percutaneous), diabetesmellitus, peripheral
arterial disease, previous history of cerebrovascular disease, any malig-
nancy, or active inflammatory disorders, and anatomical conditions pre-
cluding FD-OCT such as significant tortuosity, and severe calcification.
FD-OCT was performed prior to culprit lesion PCI following maximal
vessel dilatation with intra-coronary glyceryl trinitrate. A DragonflyTable 1
Baseline patient characteristics. NSTEMI = Non-ST elevation myocardial infarction; CAD= Cor
Angiotension-2 receptor blocker.
Variables Stable Angina (n = 47)
Age (years) 62.6 ± 6.7
Male Sex 34 (72.3%)
Body Mass Index (kg/m2) 27 ± 4.2
Smoker 19 (40.4%)
Hypertension 29 (61.7%)
Family history of CAD 24 (51.1%)
History of Hyperlipidaemia 28 (59.6%)
Haemoglobin (g/L) 14.2 ± 0.98
White cell count (×109/L) 7.3 ± 1.7
Platelet count ((×109/L) 246 ± 62.3
Glomerular filtration rate (ml/min/1.73 m2) N60
Glucose (mmol/L) 5.2 ± 0.8
Total cholesterol (mmol/L) 4.5 ± 1.2
Non-HDL cholesterol (mmol/L) 3.13 ± 1.05
Triglyceride (mmol/L) 1.4 ± 1.1
LV ejection fraction 62.2 ± 7.2%
Medication
Aspirin 47 (100%)
Thienopyridine 47 (100%)
Beta blocker 40 (81.6%)
ACE inhibitors 32 (65.3%)
A2RB 7 (14.3%)
Statins 47 (100%)
Calcium channel antagonist 12 (24.5%)
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timisation system, California, USA) was used utilising a 2.7-French
monorail delivered through a 6-French guide catheter over a standard
0.014-inch intra-coronary guidewire. This rapid exchange monorail-
imaging catheter was connected to a central console containing the
light source, image processing software and imaging display (ILUMIEN
OPTIS PCI Optimisation system). The image analysis was performed
off-line using QCU-CMS software (LKEB, Leiden, The Netherlands). The
region of interest included at least 30mmof themost proximal acquired
coronary segment. Frames at 1mm intervals were analysed. Each frame
was characterized according to one of the following plaque types: nor-
mal vessel (no plaque), fibrous plaque, fibrocalcific and fibroatheroma.
The latter was further categorized into thin (fibrous cap ≤ 65 μm) or
thick-cap fibroatheroma (N65 μm).
Bloodwas taken from the arterial sheath immediately before PCI and
PBMC isolated using the Optiprep™ gradient centrifugation as previ-
ously described [9]. Nuclear protein extracts were prepared from
PBMCs using the NE-PER™ Nuclear and Cytoplasmic Extraction Re-
agents Kit, according tomanufacturer's guidelines (ThermoFisher Scien-
tific, Massachusetts, USA) and protein concentrations determined using
the BCA Protein Assay kit (ThermoFisher Scientific, Massachusetts,
USA). Nuclear DNA repair activity was measured using a microplate-
based DNA ligase assay. DNA ligase and DNA polymerase repair activi-
ties were quantified using microplate-based assays, one in which
double stranded oligonucleotide substrates containing either a single
ligatable strand nick or a strand nick with a single nucleotide gap
immobilised on the surface of the wells were repaired by the enzyme
present in the extracts. Serial dilutions of recombinant T4 DNA ligase
or exonuclease minus Klenow fragment (Promega) in the presence of
excess T4 DNA ligase were used to construct standard curves from
which the nuclear extract activities were interpolated. There was a
strong correlation between activities determined with the two assays.
Since the gap filling assay measures the combined repair activity of
DNA polymerase and DNA ligase whereas the ligase assay only mea-
sures the latter, such a correlation suggests that either expression of
the DNA ligase and polymerase activity is closely coordinated or that
the ligation step is rate limiting in the gap-filling assay. Spiking of nu-
clear extracts sampleswith excess exonucleaseminus Klenow fragment
DNA polymerase had no substantial effect on the apparent gap-fillingonary artery disease; LV = Left ventricle; ACE = Angiotensin converting enzyme; ARB =
NSTEMI (n = 42) Control (n = 35) p Value
58.1 ± 12.1 57.8 ± 9.7 0.08
33 (78.6%) 20 (57.1%) 0.13
27.7 ± 5.9 27.7 ± 4.6 0.75
29 (69%) 13 (37.1%) 0.008
22 (52.4%) 8 (22.9%) 0.003
20 (47.6%) 8 (22.9%) 0.03
12 (28.6%) 7 (20%) b0.001
14.5 ± 1.3 14.3 ± 1 0.6
8.7 ± 2.8 7.1 ± 1.6 b0.001
233.9 ± 55.8 253.9 ± 53.6 0.32
N60 N60 1.0
5.4 ± 0.9 5 ± 0.6 0.16
4.7 ± 1.2 5.1 ± 0.8 0.07
3.6 ± 1.0 3.5 ± 0.8 0.15
1.5 ± 1.2 1.6 ± 0.9 0.85
62.1 ± 4.5% 63.6 ± 3.6% 0.47
42 (100%) 11 (31.4%) b0.001
42 (100%) 1 (2.9%) b0.001
38 (90.5%) 7 (20%) b0.001
40 (95.2%) 7 (20%) b0.001
2 (4.8%) 0 (0%) 0.03
42 (100%) 9 (25.7%) b0.001
2 (4.8%) 6 (17.1%) 0.04
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Table 2
Angiographic, procedural characteristics, and FD-OCT based measurements of plaque
morphology. The OCT data are presented as mean ± one standard deviation.
NSTEMI=Non-ST-elevation myocardial infarction; AHA = American Heart Association.
Plaque categories are the percentages of the plaque categories along each subject's vessel
averaged over all subjects.
Variable Stable Angina
(n = 47)
NSTEMI
(n = 42)
p value
Culprit vessel
Proximal left anterior descending 15 (31.9%) 8 (19%) 0.21
Mid left anterior descending 18 (38.3%) 19 (45.2%) 0.35
Circumflex artery 6 (12.8%) 2 (4.8%) 0.20
Right coronary artery 10 (21.3%) 13 (31%) 0.26
AHA lesion classification
A 17 (36.2%) 12 (28.6%) 0.54
B 31 (66%) 30 (71.4%) 0.41
C 1 (2.1%) 0 (0%) 0.32
Syntax score 7.7 ± 4.4 10.3 ± 5.6 0.03
Plaque category (%)
Normal vessel 26.6 ± 21.7 23.0 ± 19.6 –
Thin capped fibroatheroma 17.0 ± 10.4 26.4 ± 20.5 –
Thick capped fibroatheroma 25.3 ± 16.6 24.7 ± 17.0 –
Fibrous plaque 38.1 ± 17.5 39.0 ± 26.4 –
Fibrocalcific plaque 26.8 ± 26.0 23.4 ± 25.3 –
3N. Shah et al. / Cardiovascular Revascularization Medicine xxx (xxxx) xxxactivitywhereas spiking extractswith extra DNA ligase dramatically en-
hanced the apparent gap filling activity. This suggests that the correla-
tion observed was because the DNA ligase activity in the nuclear
extracts was the rate-limiting step of the two. Consequently, only the
DNA ligase activity data are presented.
Gene expression analysis by quantitative reverse transcription poly-
merase chain reaction (qRT-PCR) for 22 human DDR genes was
outsourced to Qiagen (Hilden, Germany). These genes have previously
been found to exhibit themost consistent and significant differential ex-
pression in cultured human VSMCs and atherosclerotic plaques ex-vivo
from an original 84 gene human DDR pathway array. All FD-OCTs were
analysed with blinded patient's background at the MedstarFig. 1. Examples of atherosclerotic plaques visualised by frequency domain optical coher
fibroatheromatous (D) lesions are identified.
Please cite this article as: N. Shah, L.B. Meira, R.M. Elliott, et al., DNA damag
plaque morphology u..., Cardiovascular Revascularization Medicine, https:Cardiovascular Research Network Core Laboratory, MedStar
Washington Hospital Centre, DC (USA) using internationally recognised
guidelines [10,11].
In the absence of published data regarding parameters such as DNA
ligase activity in humans with and without atherosclerosis, a sample
size of 30 patients per group was recommended to detect an effect
size of 0.9 with a power of 80% and 2-tailed α of 0.05. In total, 124
were recruited to comfortably allow for three cohorts of at least 30 pa-
tients. Statistical analysis was performed using SAS, version 8.2 (SAS
Institute, Cary, North Carolina). Continuous variables and categorical
variables are expressed as mean ± standard deviation respectively.
Clinical demographicswere analysed using a 1-wayAnalysis of Variance
(ANOVA) or 2-tailed unpaired t-test withWelch correction as appropri-
ate. DNA ligase activity and gene expression data were analysed using a
1-way ANOVA. Bonferroni's correction was used for pair wise compari-
sons for control versus SA, control versus NSTEMI, and SA versus
NSTEMI. The gene expression data were compared using the student's
t-test and the q-value calculated using Benjamini and Hochberg
method. This q-value gives the minimum False Discovery Rate (FDR)
at which the test may be called significant. Differences were considered
significant for q-values b0.05. Correlation between FD-OCT plaque pa-
rameters and gene expression/DNA ligase activity was analysed using
Spearman rank correlation. Hierarchical cluster analysis of the correla-
tion matrix was used to assess associations of the rows (gene expres-
sion) and columns (plaque parameters). A Heatmap overlaid on the
clusters displays the rows and columns as rectangles scaled along a col-
our gradient indicating the strength of associations.
3. Results
The baseline characteristics of the three groups of patients are sum-
marized in Table 1. The three groups differed in the rates of smoking,
hypertension, family history of CAD, history of hyperlipidaemia, total
white cell count, and secondary prevention medication, which were
all increased in CAD patients. All SA and NSTEMI patients were onThin fibrous cap 
overlying lipid-rich 
atheroma (TCFA)
ent tomography (FD-OCT). Fibrotic (A), Fibrocalcific (B), lipid rich (C), and thin-cap
e and repair in patients with coronary artery disease: Correlationwith
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Table 3
Comparison of gene expression in control and stable anginapatients. CI LB=Lower bound
of the 95% Confidence interval; CI UB=Upper bound of the 95% Confidence Interval. As
compared to controls, patients with SA demonstrated significant down-regulation of
genes involved in the DSBR pathway (BRAC1, RBBP8, RAD50, XRCC6), nucleotide excision
repair pathway (XPA, DDB1, and CDK7), transcriptional mediators such as ABL1 and
SUMO1, and up-regulation of OGG1, involved in BER, MLH3, involved in mismatch repair,
and GADD45A, a p53 target.
Probe ID Control Stable q-Value
Mean CI LB CI UB Mean CI LB CI UB
CDK7 16.3 15.0 17.6 12.1 11.3 12.8 b0.001
RAD50 15.9 14.3 17.4 11.3 10.3 12.4 b0.001
MLH3 26.5 20.6 32.4 51.9 43.8 60.1 b0.001
DDB1 65.5 62.1 68.9 55.0 52.0 58.0 b0.001
OGG1 7.8 7.1 8.5 11.0 9.9 12.1 b0.001
SUMO1 31.8 30.0 33.5 27.6 26.1 29.0 b0.001
ABL1 9.1 8.2 10.0 7.5 6.9 8.2 b0.001
RBBP8 5.6 5.1 6.1 4.5 4.0 5.0 0.01
BRCA1 2.6 2.3 2.8 2.0 1.8 2.3 0.01
GADD45A 0.6 0.5 0.8 1.1 0.8 1.4 0.01
XPA 3.5 3.0 4.0 2.8 2.4 3.2 0.04
XRCC6 30.9 28.8 33.0 28.5 26.9 29.9 0.09
MRE11 16.9 15.3 18.5 14.9 13.5 16.4 0.11
CHEK1 1.5 1.2 1.8 1.2 0.9 1.5 0.16
GTSE1 0.3 0.1 0.4 0.5 0.3 0.6 0.18
PRKDC 4.5 4.0 5.0 4.0 3.6 4.5 0.18
ATM 22.1 19.4 24.9 19.8 17.9 21.7 0.18
NLRP2 3.1 2.1 4.1 3.0 2.4 3.6 0.9
ERCC2 3.0 2.6 3.4 3.0 2.7 3.3 0.92
EBNA1BP2 22.0 20.5 23.6 22.3 20.3 24.2 0.92
TP73 0.1 0.1 0.2 0.1 0.1 0.2 0.93
ERCC1 14.2 13.1 15.4 14.1 13.0 15.3 0.94
4 N. Shah et al. / Cardiovascular Revascularization Medicine xxx (xxxx) xxxstatins but a greater proportion of NSTEMI patients were on an angio-
tensin converting enzyme inhibitor (ACEI).
The angiographic and procedural characteristics as well as the OCT
parameters are summarized in Table 2. The culprit vessel and the
American Heart Association lesion classification were similar in the
two groups. The SYNTAX score was low in both groups but significantly
higher in NSTEMI patients (10.3 ± 5.6 vs. 7.7 ± 4.4; p= 0.03). The FD-
OCT parameters measured included lipid-rich plaque, which has been
further characterized into thin or thick-cap fibroatheroma depending
on the fibrous cap thickness (65 μmwas used as the criteria with mea-
surements b65 μm defining a thin-cap fibroatheroma), fibrous plaque
and fibrocalcific plaque (Fig. 1).
The mean DNA ligase activity was different across the three groups
of patients (control = 119 ± 53, NSTEMI = 115.6 ± 85.1, SA = 81 ±
55.7 units/g of nuclear protein; ANOVA p = 0.023) (Fig. 2). Pair wise
comparison demonstrated that this significance arose due to differences
between the control and SA patients (p = 0.046). There was no
correlation between ligase activity and age (r = −0.094), total
cholesterol (r= 0.013), or total white cell count (r= 0.027).
As compared to controls, patients with SA demonstrated significant
down-regulation of genes involved in the DSBR pathway (BRCA1,
RBBP8, RAD50, XRCC6), nucleotide excision repair pathway (XPA,
DDB1, and CDK7), transcriptional mediators such as ABL1 and SUMO1,
and up-regulation of OGG1, involved in BER, MLH3, involved in mis-
match repair, and GADD45A, a p53 target (Table 3). As compared to
control subjects, NSTEMI patients had down-regulation of RAD50,
CDK7, as well as SUMO1 and up-regulation of OGG1 (Table 4).
Heatmaps of DDR gene expression are shown in Figs. 3 and 4. The
Heatmap indicates that in patients with SA, fibrocalcific plaques are
strongly associated with GTSE1, DDB1, MLH3 and ERCC1 expression.
By contrast, in NSTEMI patients the strongest association was observed
between ATM and XPA with fibrous plaques.Table 4
Comparison of gene expression in control and non-ST elevation myocardial infarction
(NSTEMI) patients. CI LB = Lower bound of the 95% Confidence interval; CI UB=Upper
bound of the 95%Confidence Interval. In patientswithNSTEMI,we founddown-regulation
of RAD50, CDK7, and SUMO1 and up-regulation of OGG1.
ProbeID Control NSTEMI q-Value4. Discussion
This study demonstrates proof of concept that patients with CAD ex-
hibit alterations in DNA repair andDDR gene expression, some of which
are associated with plaque morphology. This is the first description to
our knowledge of such findings in patients with CAD.
Accumulating data over the past two decades has implicated the
DDR as an essential feature of atherosclerosis [12,13]. For example in
rabbit models of atherosclerosis, DNA strand breaks normalized within
weeks of statin therapy but 8-oxo-G immunoreactivity persisted
significantly longer implying that DNA repair is inefficient in atheroscle-
rosis [12]. Similarly, apolipoprotein-deficient mice that were
haploinsufficient for ATM have also been shown to exhibit persistentDN
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Fig. 2.DNA ligase activity in patients with stable angina (SA), non-ST elevationmyocardial
infarction, as well as age and gender-matched controls (ANOVA = 0.023). Pair wise
comparison demonstrated that this significance arises due to differences between the
control and SA patients (p= 0.046).
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eration, apoptosis and mitochondrial dysfunction [13]. By contrast,
there is limited data on DNA repair in human atherosclerosis. PBMCs
isolated from patients with SA and acute coronary syndromes showed
evidence of DNA damage including shortened telomeres andmitochon-
drial DNA damage [14]. Monocytes from these patients showed
increased basal and lipopolysaccharide–induced cytokine releaseMean CI LB CI UB Mean CI LB CI UB
CDK7 16.3 15.0 17.6 13.1 12.3 13.9 b0.001
OGG1 7.8 7.1 8.5 10.5 9.1 11.8 0.01
RAD50 15.9 14.4 17.4 13.3 12.2 14.3 0.03
SUMO1 31.7 30.0 33.5 28.6 27.1 30.1 0.04
MLH3 26.5 20.6 32.4 38.8 30.7 47.0 0.074
ABL1 9.1 8.2 9.9 7.9 7.3 8.5 0.75
XPA 3.5 3.0 3.9 3.0 2.7 3.3 0.18
TP73 0.1 0.1 0.2 0.1 0.1 0.1 0.20
ERCC2 3.0 2.6 3.4 3.4 3.1 3.7 0.20
ATM 22.1 19.4 24.9 19.4 17.6 21.2 0.20
ERCC1 14.2 13.1 15.4 15.4 14.2 16.6 0.34
MRE11 16.9 15.3 18.5 15.7 14.3 17.1 0.47
GADD45A 0.6 0.5 0.8 0.7 0.6 0.8 0.50
RBBP8 5.6 5.1 6.1 5.2 4.6 5.8 0.50
CHEK1 1.5 1.2 1.8 1.3 0.9 1.8 0.63
GTSE1 0.3 0.1 0.4 0.3 0.2 0.4 0.63
NLRP2 3.1 2.1 4.1 3.6 2.6 4.7 0.62
EBNA1BP2 22.0 20.5 23.6 21.5 20.3 22.7 0.71
BRCA1 2.6 2.3 2.8 2.5 2.2 2.7 0.72
DDB1 65.5 62.1 68.9 64.5 61.1 67.8 0.72
PRKDC 4.5 4.0 5.0 4.5 4.1 4.9 0.88
XRCC6 30.9 28.8 33.0 31.0 29.3 32.6 0.96
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Fig. 3. ClusteredHeatmap in patients with stable angina. There are strong associations between GTSE1, DDB1, MLH3 and ERCC1 expression and fibrocalcific plaques. Low_lipid= thin-cap
fibroatheroma; High_lipid = Thick-cap fibroatheroma.
5N. Shah et al. / Cardiovascular Revascularization Medicine xxx (xxxx) xxx(MCP-1, IL-6, and IL-1ß) and increased production of reactive oxygen
species indicating that DNA damage may promote a pro-inflammatory
monocyte/macrophage phenotype. Indeed, DNA damage using the
telomere-disrupting agent telomestatin reproduced this phenotype
and both telomere shortening and mitochondrial DNA damage were
correlated with thin-cap fibroatheroma indicating that DNA damage in
peripheral circulating cells may promote an unstable plaque phenotype
[14].
Cultured human aortic VSMCs have been shown to exhibit robust
changes in the expression of 22 DDR genes [8]. We therefore elected
to study the expression of these genes in our study. As compared to con-
trol subjects, we find that patients with SA exhibit a wide range of ab-
normalities in the expression of DDR including reduced expression ofPlease cite this article as: N. Shah, L.B. Meira, R.M. Elliott, et al., DNA damag
plaque morphology u..., Cardiovascular Revascularization Medicine, https:genes implicated in DSBR and NER, as well as increased expression of
certain genes involved in BER and transcriptional mediators such as
SUMO1. GTSE1, MLH3, and ERCC1 were strongly associated with
fibrocalcific plaques. This bears remarkable resemblance to the pub-
lished in vitro data [8]. DNA ligase activitywas also significantly reduced
in SA patients. By contrast, patients with NSTEMI had alterations in the
expression of RAD50, CDK7, SUMO1 and OGG1. ATM and XPA expres-
sionwas strongly associatedwith fibrous plaques. Collectively, these re-
sults indicate that the contribution of DDR gene expression and DNA
ligase activity to the atherosclerotic process may be different in patients
with SA and NSTEMI. Post-mortem studies have indicated that 60–70%
of myocardial infarctions are caused by rupture of thin-capped
fibroatheromata in which a thin cap containing macrophages separatee and repair in patients with coronary artery disease: Correlationwith
//doi.org/10.1016/j.carrev.2019.04.028
Fig. 4. Clustered Heatmap in patients with non-ST elevationmyocardial infarction. There are strong associations between ATM andXPA expression and fibrous plaques. Low_lipid= thin-
cap fibroatheroma; High_lipid = Thick-cap fibroatheroma.
6 N. Shah et al. / Cardiovascular Revascularization Medicine xxx (xxxx) xxxthe necrotic core from the lumen, oftenwithout significant vessel steno-
sis [15]. Furthermore, such lesions tend to have larger necrotic cores,
and fewer VSMCs than lesions in SA. We speculate that differences in
plaque composition between SA and NSTEMI as well as differences in
the inflammatory status of such patientsmay, at least in part, be respon-
sible for differences in DNA repair activity and the expression profiles of
genes involved in the DDR. One caveat to this argument is the higher
proportion of NSTEMI patients who were on ACEI. This family of drugs
have been shown to reduce the production of reactive oxygen species
and consequent DNA damage through telomere-dependent and non-
telomeric pathways [3].
In addition to differences in ligase activity and the expression of DDR
genes, we have found associations between the expression of suchPlease cite this article as: N. Shah, L.B. Meira, R.M. Elliott, et al., DNA damag
plaque morphology u..., Cardiovascular Revascularization Medicine, https:genes and plaque morphology. Crosstalk between plaque and the
circulation have been noted in other studies such as PROSPECT in
which circulating CRP concentrations predicted the rate of major ad-
verse coronary events (MACE); 13.8% of thin-cap fibroatheromatous
non-culprit lesions were linked to MACE in those with CRP
concentrations N 10 mg/l compared with only 1.9% in patients with
CRP concentrations b 3 mg/l [16]. A number of studies have indicated
that DDR genes have important roles in the development of atheroscle-
rosis. For example, OGG1(−/−) Ldlr(−/−) mice fed aWestern diet de-
veloped increased plaque size and lipid content [17]. The plaques
contained increased oxidized mitochondrial DNA, inflammasome acti-
vation, and apoptosis whilst there were elevations in serum IL-1ß, and
IL-18. Restoration of OGG1 status protected against these changes ande and repair in patients with coronary artery disease: Correlationwith
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7N. Shah et al. / Cardiovascular Revascularization Medicine xxx (xxxx) xxxreduced plaque size. OGG1 has also been shown to be a key regulatory
enzyme for 8-oxoguanine repair in VSMCs with OGG1 (−/−) mice
showing increased levels of 8-oxoguanine in vivo and increased athero-
sclerosis [18]. Furthermore, ATM (+/−) ApoE (−/−) mice develop ac-
celerated atherosclerosis and features of the metabolic syndrome
including hypertension, hypercholesterolemia, obesity, and impaired
glucose tolerance [13]. Smooth muscle cells and macrophages from
such mice showed increased nuclear DNA damage, defective DNA re-
pair, growth arrest and apoptosis.
There are a number of limitations to our study. Firstly, we havemea-
sured nuclear DNA ligase activity in PBMCs rather than individual cellu-
lar components, in particular peripheral monocytes. Although this may
have been more informative, lymphocytes, monocytes, and neutrophil
activity are all implicated in atherosclerosis. Secondly, our study is de-
scriptive and does not provide a mechanism by which DNA ligase activ-
ity and DDR gene expression contribute to atherosclerosis. Thirdly, as
our patient cohort had a low SYNTAX score we cannot be certain that
our findings can be extrapolated to those with intermediate and high
SYNTAX scores. However, it is likely that such patients may exhibit a
more pronounced alteration in DNA ligase activity and genes involved
in the DDR.
5. Conclusion
In conclusion, we found that patients with CAD exhibit alterations in
their ability to repair DNA damage and DDR gene expression. Such
alterations may contribute to the development and progression the
atherosclerotic process.
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